Selecting the most appropriate therapeutic regimen for the individual patient is a great clinical challenge. Since the variability in blood pressure (BP) level has been associated with the genetic profile, it has been speculated that the application of genetic information may be useful for implementation of subject-oriented antihypertensive treatment. 1 The objective of the present study was to investigate the association between (i) polymorphisms of angiotensin-converting enzyme (ACE; insertion/deletion: II/ID/DD), angiotensinogen (AGT; MT235: MM/TT/MT), angiotensin II type 1 receptor (AT 1 R; A1166C: AA/AC/CC) and alpha-adducin (ADC; Gly460Trp, allele Trp460: GG/GW/WW), and (ii) antihypertensive responses to ACE inhibition and AT 1 R blockade. For this purpose, data from two crossover comparative trials of an ACE inhibitor vs an AT 1 R blocker conducted using ambulatory BP (ABP) monitoring were analysed.
Both studies were conducted at the Hypertension Center, Third University Department of Medicine, Athens, Greece. In study 1 2 nondiabetic, untreated Greeks with average awake diastolic ABP4 85 mmHg were randomized to receive lisinopril 20 mg or telmisartan 80 mg for 5 weeks, and were subsequently crossed-over to the alternative treatment for a second 5-week period. Study 2 was a previously published comparative study 3 of lisinopril 20 mg vs losartan 50 mg using identical inclusion criteria and design as study 1. ABP was monitored in both studies for 24 h before randomization and on the final day of each randomized period using noninvasive oscillometric devices SpaceLabs 90207. Blood samples were taken for genotyping analysis at the end of each study, whereas no subject participated in both studies. Genomic DNA was extracted from peripheral blood leucocytes and polymorphisms were detected by polymerase chain reaction. 4 Genotyping was performed at the MRC Blood Pressure Group, Western Infirmary, Glasgow, UK. The protocols and the process for obtaining informed consent were approved by the hospital scientific committee.
Analysis was performed using the Statistical Package for Social Sciences software (SPSS). Treatment effects were assessed by paired t-tests, whereas associations between BP decline and polymorphisms were examined by analysis of variance. Area under the ABP decline-time curve (AUC, mmHg Â h) was calculated using the trapezoidal rule. 5 Responders and nonresponders to each drug were defined as subjects with systolic or diastolic BP decline 475th and o25th percentile, respectively, of the decline in the total population of each study. Comparisons between allele frequencies were made by w 2 test. Multiple contingency table analysis was used to compare frequencies of polymorphisms detected in responders to lisinopril between the two studies.
In study 1 (32 subjects, 26 men, mean age 49.577.1 years, BMI 28.873.9 kg/m 2 , 13 smokers), no difference in antihypertensive efficacy was detected between the telmisartan and lisinopril (mean 24-h ABP difference 1.277.1 mmHg, 95% CI À1.4, 3.8 (systolic); mean 24-h ABP difference 0.775.1 mmHg, 95% CI À1.2, 2.5 (diastolic)). In study 2 (27 subjects, 16 men, mean age 46.679.1 years, BMI 28.273.3 kg/m 2 , 12 smokers), there was a greater BP reduction with lisinopril compared with losartan (mean 24-h difference 5.178.5 mmHg, 95% CI 1.7, 8.5, Po0.01 (systolic); mean 24-h difference 3.576.1 mmHg, 95% CI 1.1, 5.9, Po0.01 (diastolic)). No difference was detected in BP decline with lisinopril between studies 1 and 2 (1.572.2 mmHg, 95% CI À5.7, 3.1 (systolic); 0.971.6 mmHg, 95% CI À3.4, 2.9 (diastolic)). Table 1 shows BP decline-time AUC per polymorphism on each drug in both studies. Differences for each set of three subgroups were nonsignificant for all genotypes, the same observation accounting for separate analyses of men and women as well as of smokers and nonsmokers. Moreover, no specific polymorphism pattern was detected for responders and nonresponders, whereas no association was found between responders to lisinopril in study 1 and those in study 2 regarding the distribution of polymorphism subgroups, for both systolic BP (P ¼ 0.31) and diastolic BP (P ¼ 0.24).
The main findings of this study are that (i) there seems to be no association between RAS or ADC polymorphisms and BP response to ACE inhibition or AT 1 R blockade and (ii) no specific genotyping profile appears to characterize responders and nonresponders to these drug classes. Interestingly, responders to lisinopril in the two studies have no similarity in terms of the latter polymorphisms. This observation is in line with the view that BP response to an ACE inhibitor is not guided by a defined combination of the latter polymorphisms.
The extent to which RAS polymorphisms influence the differences in BP response to drug therapy remains controversial, 1 whereas in regard to ADC, it has been shown that hypertensive patients with the 460W allele have a greater BP fall, 6 and a lower risk of myocardial infarction and stroke 7 when treated with diuretics as compared to other antihypertensive drugs. Disagreement in results of such investigations may be attributed to the application of different study design, the use of different endpoints as well as to genetic diversity between populations. 1 Further, according to segregation-linkage analyses, studies evaluating associations between a trait and a particular polymorphism cannot exclude a relation of the examined trait to another polymorphism at the same locus, inasmuch as linkage disequilibrium between causative variants and tested polymorphisms may be incomplete or absent. 1 Moreover, BP in sustained hypertension might be determined to a greater degree by counterbalancing physiologic adaptations than by polymorphism-driven mechanisms. 8 Since pharmacogenetic studies require a large sample size in order to have sufficient power, an impracticably large number of 242 individuals should have been enrolled, had a parallel design and office BP measurements been used in this study. However, although the present study included a small number of subjects, its power was increased, first because a crossover design (where all patients are exposed to all treatments) was employed, 9 and, second, by using ABP monitoring that is known to have superior reproducibility than clinic BP measurements. 10 Nevertheless, the possibility of a type 2 error cannot be ruled out in our investigation.
In conclusion, the findings of the present study provide no support to the hypothesis that the genetic polymorphisms studied could be used as guidance to predict BP responses to ACE inhibition and AT 1 R blockade in patients with essential hypertension. 
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